human prostate cancer cell
Recently Published Documents


TOTAL DOCUMENTS

511
(FIVE YEARS 47)

H-INDEX

56
(FIVE YEARS 4)

2021 ◽  
Vol 26 (5) ◽  
pp. 884-913
Author(s):  
Leo Turner ◽  
Andrew Burbanks ◽  
Marianna Cerasuolo

Prostate cancer represents the second most common cancer diagnosed in men and the fifth most common cause of death from cancer worldwide. In this paper, we consider a nonlinear mathematical model exploring the role of neuroendocrine transdifferentiation in human prostate cancer cell dynamics. Sufficient conditions are given for both the biological relevance of the model’s solutions and for the existence of its equilibria. By means of a suitable Liapunov functional the global asymptotic stability of the tumour-free equilibrium is proven, and through the use of sensitivity and bifurcation analyses we identify the parameters responsible for the occurrence of Hopf and saddle-node bifurcations. Numerical simulations are provided highlighting the behaviour discovered, and the results are discussed together with possible improvements to the model.


2021 ◽  
Author(s):  
Dejan Simic ◽  
Milan Zaric ◽  
Ivana Nikolic ◽  
Radica Zivkovic Zaric ◽  
Petar Canovic ◽  
...  

A five new complexes of palladium(II) ion (C1–C5) general formula [PdL2)]Cl2 with some 2-aminothiazoles (L1-L5) where L1 = 2-amino-4-(3,4 difluorophenyl) thiazole, L2 = 2-amino-5-methyl-4-phenylthiazole, L3 = 2-amino-4-phenylthiazole, L4 = 2-amino-4-(4-chlorophenyl)...


Molecules ◽  
2020 ◽  
Vol 26 (1) ◽  
pp. 56
Author(s):  
Sahar B. Kandil ◽  
Christopher McGuigan ◽  
Andrew D. Westwell

The androgen receptor (AR) is a pivotal target for the treatment of prostate cancer (PC) even when the disease progresses toward androgen-independent or castration-resistant forms. In this study, a series of 15 bicalutamide analogues (sulfide, deshydroxy, sulfone, and O-acetylated) were prepared and their antiproliferative activity evaluated against four different human prostate cancer cell lines (22Rv1, DU-145, LNCaP, and VCap). Bicalutamide and enzalutamide were used as positive controls. Seven of these compounds displayed remarkable enhancement in anticancer activity across the four PC cell lines. The deshydroxy analogue (16) was the most active compound with IC50 = 6.59–10.86 µM. Molecular modeling offers a plausible explanation of the higher activity of the sulfide analogues compared to their sulfone counterparts.


Sign in / Sign up

Export Citation Format

Share Document